The Convergence of Nanoscience and Stem Cells: A New Era in Cancer Therapeutics.
1/5 보강
Cancer remains one of the leading causes of global mortality, yet its treatment is frequently limited by poor drug distribution, systemic toxicity, and therapeutic resistance.
APA
Raveendran AP, G R, et al. (2026). The Convergence of Nanoscience and Stem Cells: A New Era in Cancer Therapeutics.. Biotechnology journal, 21(2), e70188. https://doi.org/10.1002/biot.70188
MLA
Raveendran AP, et al.. "The Convergence of Nanoscience and Stem Cells: A New Era in Cancer Therapeutics.." Biotechnology journal, vol. 21, no. 2, 2026, pp. e70188.
PMID
41645572 ↗
Abstract 한글 요약
Cancer remains one of the leading causes of global mortality, yet its treatment is frequently limited by poor drug distribution, systemic toxicity, and therapeutic resistance. Stem cells with their self-renewal capacity, lineage-specific differentiation, and intrinsic tumor-homing ability have attracted considerable attention as potential mediators of targeted cancer therapy. Concurrently, nanotechnology offers tunable physicochemical properties and advanced tissue penetration, providing versatile platforms for drug delivery, imaging, and diagnostics. The convergence of nanotechnology and stem cell biology has expanded the therapeutic landscape, enabling multifunctional strategies for targeted drug delivery, imaging, and diagnostics. This review examines the challenges of drug delivery in oncology, elucidates the biological rationale for stem cell-mediated therapies, and explores the role of nanotechnology in augmenting their potential, emphasizing how the tumor-homing capacity of stem cells can be exploited to overcome major barriers in conventional therapies. Furthermore, limitations, safety concerns, and the status of preclinical, and clinical development are discussed, with a focus on key research gaps and future directions to advance this interdisciplinary field.
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
같은 제1저자의 인용 많은 논문 (1)
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.